| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | AgNovos Bioscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $257.83M | Series B | 12/20/2023 | $44.85M | $338.24M | $35.76 | Undisclosed Investors | ||||
 | Ampersand Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.61M | Series B | 3/19/2025 | $65M | $360.94M | $5.80 | Flagship Pioneering, Eli Lilly & Company | ||||
 | ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B | 12/16/2022 | $110M | $375.08M | $1.05 | Undisclosed Investors | ||||
 | BioTheryX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.09M | Series E | 5/20/2021 | $100M | $348.42M | $5.25 | Farallon Capital Management, Avidity Partners, Deep Track Capital, Irving Investors, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital management, Alexandria Ventur Investors, Wedbush Helthcare Partners | ||||
 | CAMP4 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $113.77M | Series B | 7/20/2022 | $100.54M | $297.52M | $1.47 | Patient Square Capital, Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group | ||||
 | cAMPfield Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180M | Series A | 6/18/2026 | $177.98M | $297.85M | $5.22 | Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital | ||||
 | Caribou Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $156.62M | Series A-1 | 4/2/2025 | $8M | $30.49M | $2.66 | Fidelity, Novartis, Mission Bay Capital, 5 Prime Ventures, Jennifer Doudna, F-Prime | ||||
 | Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $262M | Series B | 3/1/2023 | $135M | $450.56M | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | ||||
 | ClearDATA | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $160.84M | Series E | 11/19/2018 | $26M | $220.91M | $0.77 | Excel Venture Management, Flare Capital Partners, HCSC Ventures, Heritage Group, HLM Venture Partners, Merck Global Health Innovation Fund | ||||
 | ClearNote Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $138.62M | Series D | 5/27/2026 | $26.73M | $275.59M | $8.10 | Prosperity Capital Management, Sandy Weill, Stephen Quake | ||||
 | Codiak BioSciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.37M | Series C | 11/29/2017 | $76.37M | $404.14M | $3.78 | ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, Alexandria Venture Investments | ||||
 | Cooler Heads | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $23.97M | Series A-3 | 7/10/2026 | $3.27M | $34.04M | $1.15 | Undisclosed Investors | ||||
 | HealthTap | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.45M | Series B | 11/6/2024 | $28.05M | $44.1M | $0.21 | Undisclosed Investors | ||||
 | Hill Research | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $34.94M | Series Strategic | 9/15/2026 | $16.85M | $300.33M | $14.24 | -- | ||||
 | ION Clean Energy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $74.4M | Series A | 4/4/2024 | $74.4M | $254.58M | $6.97 | Chevron, Carbon Direct Capital, SK Materials | ||||
 | Ionetix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $98.68M | Series F | 8/7/2024 | $62.72M | $266.93M | $1.40 | Eli Lilly, POINT Biopharma Global | ||||
 | Jnana Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $414.4M | Series C-2 | 11/15/2022 | $47M | $292.93M | $0.89 | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | ||||
 | Noyo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $61.51M | Series B-2 | 5/19/2022 | $22.09M | $310.32M | $9.30 | Norwest Venture Partners, Workday Ventures, Gusto, Cap Table Coalition, Costanoa Ventures, Spark Capital, Homebrew, Operator Collective, Fika Ventures, Precursor Ventures, Garuda Ventures, Core Innovation Capital, Webb Investment Network | ||||
 | Octagos Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $53.16M | Series B | 7/9/2024 | $28.73M | $107.58M | $31.13 | Morgan Stanley, Mucker Capital | ||||
 | Orphai Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $124.32M | Series 1-E | 8/1/2021 | $28.37M | $189.3M | $1.34 | Undisclosed Investors | ||||
 | Ostro | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.67M | Series B-1 | 4/23/2025 | $5.75M | $90.55M | $2.17 | Havas | ||||
 | Ratio Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $151.27M | Series C | 7/31/2026 | $70M | $398.34M | $43.69 | Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group | ||||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | Secretome Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $57.53M | Series A | 5/27/2026 | $30.5M | $231.7M | $2.29 | RA Capital | ||||